NEW YORK, March 2, 2026 /PRNewswire/ -- Quick Take: Private-public crossover ETF providing access to select private companies, including SpaceX -- SPV acquisition costs already incurred -- Fund does ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Good day, and thank you for standing by. Welcome to the Structure Therapeutics top line results from the aleniglipron Phase II Access Program. [Operator Instructions] Please be advised that today's ...
PARIS--(BUSINESS WIRE)--Regulatory News: Clariane (CLARIA.PA - ISIN FR0010386334), today announces a four-part short and mid-term action plan to address the increasing constraints it faces in ...
Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.
Anna McDermott, president and CEO of the Westminster, Colo.-based distributor, said she expects much of the conference, held this year in Colorado Springs , Colo., to focus on opportunities for ...
Real-time data and analytics were labelled the most valued feature for traders, across all product categories and regions, in a new JP Morgan survey; findings come amid recent industry debate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results